Pegloticase

Pegloticase decreased serum urate in patients with uncontrolled gout who previously received a kidney transplant and were treated with more than one immunosuppressive therapy to protect against organ rejection.

In this video, Craig A. Shadur, MD, a transplant nephrologist from Des Moines, Iowa, discussed the use of pegloticase for patients with kidney transplants.

Adding immunomodulatory therapy to pegloticase for gout improves treatment persistence, according to data from a large observational registry presented at ACR Convergence 2021.

Concomitant use of methotrexate and pegloticase resulted in “meaningful” improvements in joint assessments and patient-reported outcomes at 12 months in uncontrolled gout, according to data presented at the EULAR 2021 Virtual Congress.

Concomitant use of mycophenolate mofetil with pegloticase demonstrated clinically meaningful improvement in 86% of patients with uncontrolled gout, compared with pegloticase alone, according to data published in Arthritis & Rheumatology.

A study of patients on hemodialysis found pegloticase was successful in treating gout, while also demonstrating the potential to lower erythropoiesis-stimulating agent dose requirements following the therapy.